Amicus Therapeutics Inc (NASDAQ: FOLD) kicked off on Monday, up 3.70% from the previous trading day, before settling in for the closing price of $6.48. Over the past 52 weeks, FOLD has traded in a range of $6.20-$12.65.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 24.32% over the past five years. While this was happening, its average annual earnings per share was recorded 117.76%. With a float of $296.87 million, this company’s outstanding shares have now reached $299.04 million.
Let’s look at the performance matrix of the company that is accounted for 499 employees. In terms of profitability, gross margin is 89.98%, operating margin of 4.71%, and the pretax margin is -5.44%.
Amicus Therapeutics Inc (FOLD) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Amicus Therapeutics Inc is 3.38%, while institutional ownership is 97.65%. The most recent insider transaction that took place on Feb 19 ’25, was worth 4,000. In this transaction President and CEO of this company sold 400 shares at a rate of $10.00, taking the stock ownership to the 1,150,657 shares. Before that another transaction happened on Feb 19 ’25, when Company’s Director proposed sale 400 for $9.85, making the entire transaction worth $3,940.
Amicus Therapeutics Inc (FOLD) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 117.76% per share during the next fiscal year.
Amicus Therapeutics Inc (NASDAQ: FOLD) Trading Performance Indicators
Take a look at Amicus Therapeutics Inc’s (FOLD) current performance indicators. Last quarter, stock had a quick ratio of 2.60. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.91.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.18, a number that is poised to hit -0.05 in the next quarter and is forecasted to reach 0.34 in one year’s time.
Technical Analysis of Amicus Therapeutics Inc (FOLD)
Amicus Therapeutics Inc (NASDAQ: FOLD) saw its 5-day average volume 5.1 million, a positive change from its year-to-date volume of 2.72 million. As of the previous 9 days, the stock’s Stochastic %D was 18.79%. Additionally, its Average True Range was 0.41.
During the past 100 days, Amicus Therapeutics Inc’s (FOLD) raw stochastic average was set at 12.52%, which indicates a significant decrease from 21.05% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 47.75% in the past 14 days, which was higher than the 35.00% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.77, while its 200-day Moving Average is $10.05. Nevertheless, the first resistance level for the watch stands at $6.90 in the near term. At $7.08, the stock is likely to face the second major resistance level. The third major resistance level sits at $7.29. If the price goes on to break the first support level at $6.50, it is likely to go to the next support level at $6.29. The third support level lies at $6.11 if the price breaches the second support level.
Amicus Therapeutics Inc (NASDAQ: FOLD) Key Stats
The company with the Market Capitalisation of 2.06 billion has total of 307,240K Shares Outstanding. Its annual sales at the moment are 528,300 K in contrast with the sum of -56,110 K annual income. Company’s last quarter sales were recorded 149,710 K and last quarter income was 14,740 K.
